Holen Sie sich die Stockscreener-App
1.42
7.19%
-0.11
Vorhandelsmarkt:
1.44
0.02
+1.41%
Schlusskurs vom Vortag:
$1.53
Offen:
$1.56
24-Stunden-Volumen:
8.67M
Relative Volume:
1.29
Marktkapitalisierung:
$426.53M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.9467
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-4.70%
1M Leistung:
+16.39%
6M Leistung:
+2.90%
1J Leistung:
-8.39%
1-Tages-Spanne:
$1.3735
$1.56
1-Wochen-Bereich:
$1.3735
$1.595
52-Wochen-Spanne:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.42 | 459.57M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Can Pacific Biosciences of California Inc. stock resist market sell offsWeekly Trade Review & High Win Rate Trade Alerts - newser.com
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - TradingView
Weiss Ratings Reiterates Sell (E+) Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Detecting price anomalies in Pacific Biosciences of California Inc. with AIEarnings Risk Report & Daily Growth Stock Tips - newser.com
What analysts say about Pacific Biosciences of California Inc P09 stockHealthcare Stock Analysis & Rapid Profit Growth - earlytimes.in
How HiFi sequencing achieves scalable microbial genomics without compromise - PacBio
Forecasting Pacific Biosciences of California Inc. price range with options dataWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosIndex Update & Stock Portfolio Risk Management - newser.com
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell - MSN
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Technology Chosen for Major Longevity Study - GuruFocus
7,800 Genomes & Epigenomes: PacBio Powers Long Life Family Study with Revio, Q4 2025 Start - Stock Titan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
PacBio Expands Partnership with seqWell to Distribute LongPlex™ Multiplexing Kit for Enhanced Genomic Sequencing Solutions - Quiver Quantitative
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs - Yahoo Finance
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - sharewise.com
Is Pacific Biosciences of California Inc. (P09) stock a buy before new product rollout2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Will Pacific Biosciences of California Inc. stock outperform Nasdaq indexJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Pacific Biosciences of California Inc. stock is rated strong buy2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Is this a good reentry point in Pacific Biosciences of California Inc.July 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Will Pacific Biosciences of California Inc. rebound enough to break evenJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
Is Pacific Biosciences of California Inc. a candidate for recovery playJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Heatmap analysis for Pacific Biosciences of California Inc. and competitorsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5 - 富途牛牛
Can volume confirm reversal in Pacific Biosciences of California Inc.Portfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Can swing trading help recover from Pacific Biosciences of California Inc. losses2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Powered by PacBio: Selected publications from September 2025 - PacBio
Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
PacBio Enters Carrier Screening Market With PureTarget Expansion - sharewise.com
What drives Pacific Biosciences of California Inc P09 stock priceGlobal Market Influence & Outstanding Investment Returns - earlytimes.in
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Best data tools to analyze Pacific Biosciences of California Inc. stockJuly 2025 Decliners & Verified Short-Term Plans - newser.com
Pacbio’s Puretarget simplifies carrier screening - BioWorld MedTech
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):